Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Fourth Quarter And Full Year 2014 Financial Results

      - 2014 Sales of $374.2 million and EBITDA of $82.1 million significantly exceed guidance -

      - Strong sales and EBITDA growth expected in 2015 -

      - Conference call at 8:30 a.m. ET on February 6, 2015 -


      News provided by

      Cambrex Corporation

      Feb 06, 2015, 07:00 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Feb. 6, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the fourth quarter and full year ended December 31, 2014.

      Highlights

      • Fourth quarter 2014 sales increased 25% to $128.8 million from $103.0 million in the same period last year.  Full year 2014 sales increased 18%, and 19% excluding the impact of foreign currency.
      • Fourth quarter Adjusted EBITDA increased to $34.4 million compared to $22.2 million in the same period last year.  Full year Adjusted EBITDA increased 22% to $82.1 million compared to $67.4 million in 2013.  (See table at the end of this release).     
      • Debt, net of cash, was $14.5 million at the end of the fourth quarter, an improvement of $19.0 million during the quarter.  Debt, net of cash, decreased $42.0 million for the full year 2014.
      • 2015 sales, excluding the impact of foreign currency, are expected to increase between 16% and 20% compared to 2014.  EBITDA is expected to be between $101 and $107 million, a 23% to 30% increase over 2014. Adjusted income from continuing operations is expected to be between $1.62 and $1.75 per share, a 22% to 32% increase over 2014 (see Financial Expectations section below).

      "We are very pleased with our 2014 results and expect continued strong growth in 2015," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex. "We saw increased demand across all of our product categories in 2014, and performance was particularly strong in the innovator and controlled substances markets. As our guidance suggests, we expect to maintain our positive momentum with substantial sales and EBITDA growth in 2015. We believe that our 2015 expectations and our organic cumulative annual growth rate of 13% since 2010 confirm that we are focused on the right strategic growth initiatives for our business.

      "These growth expectations and a robust pipeline of new business opportunities require us to aggressively invest in capacity to meet actual and anticipated demand. We are significantly expanding our facility in Iowa to facilitate expected strong demand for large scale cGMP capacity and are also investing in our Swedish and Italian sites. We believe we are investing at the appropriate level to enable us to take full advantage of current positive market trends and support our strategic growth initiatives."

      Basis of Reporting
      The Company has provided a reconciliation of GAAP amounts to adjusted (i.e. Non-GAAP) amounts at the end of this press release.  Management believes that the adjusted amounts provide useful information to investors due to the magnitude and nature of certain expenses recorded in the GAAP amounts.

      Fourth Quarter 2014 Operating Results – Continuing Operations
      Sales were $128.8 million, compared to $103.0 million in the same period last year, representing a 25% increase.  Foreign exchange unfavorably impacted reported sales growth by 5%.  The Company recorded sales increases in all of its product categories, with strong growth in certain branded and generic APIs.

      Gross margins increased to 35% from 33% compared to the same period last year.  This increase was primarily due to improved production efficiencies, higher plant utilization and a favorable impact from foreign exchange.

      Selling, general and administrative expenses were $13.8 million compared to $14.7 million in the same period last year.  The decrease was mainly due to lower compensation expense during the fourth quarter this year and a favorable impact from foreign exchange.

      Research and development expenses were $3.1 million compared to $2.8 million in the same period last year.  The increase was primarily the result of increased personnel costs to facilitate the development of a higher number of generic and controlled substance APIs partially offset by a favorable impact from foreign exchange.

      Operating profit increased to $22.6 million from $16.4 million in the same period last year.  The increase in operating profit was primarily the result of higher gross profit, lower operating expenses and a gain on the sale of land, all of which were partially offset by a charge related to a voluntary pension payout settlement, which is explained below. Excluding the pension settlement and the gain on the sale of land, operating profit would have been $28.5 million.  Adjusted EBITDA was $34.4 million compared to $22.2 million in the same period last year. 

      Income taxes for the quarter were a benefit of $6.2 million and included a benefit of $11.7 million for the reversal of a valuation allowance against certain U.S. tax assets, a benefit of $3.9 million primarily related to a tax audit settlement, and expense of $0.4 million related to the gain on the sale of land.  Excluding the impacts of these items, the loss on voluntary pension settlement and the gain on sale of land, the effective tax rate would have been 32% during the quarter compared to 37% in the same period last year, largely due to differences in the geographical mix of income.

      The Company had previously estimated that it would reduce its valuation allowance against certain U.S. tax assets by approximately $2.0 million during the fourth quarter of 2014.  As a result of updates to projections, the Company released $11.7 million of valuation allowance and reduced its provision for income taxes accordingly in the fourth quarter of 2014.  Additionally, during the fourth quarter of 2014, the Company settled a tax dispute with a European tax authority that arose in 2009.  As a result, the Company reversed reserves of $4.1 million related to the dispute.

      Income from continuing operations was $28.3 million or $0.89 per share compared to $9.4 million or $0.30 per share in the same period last year.  Adjusted income from continuing operations was $20.4 million or $0.64 per share, compared to $11.3 million or $0.36 per share, respectively, in the same period last year (see table at the end of this release).

      Capital expenditures and depreciation were $13.0 million and $5.7 million, respectively, compared to $9.6 million and $5.8 million, respectively, in the same period last year. 

      As part of a program to offer a one-time election to receive a voluntary lump-sum pension payout to certain former employees, the Company settled $17.4 million of its pension obligations within its U.S. plan with an equal amount paid from plan assets during the fourth quarter.  As a result, the Company recorded settlement losses of $7.2 million during the fourth quarter reflecting the accelerated recognition of unamortized losses in the U.S. pension plan proportionate to the obligation that was settled.  The loss on voluntary pension settlement is reflected as a separate line in the consolidated income statement with a corresponding balance sheet reduction in "Stockholders' Equity."

      Financial Expectations – Continuing Operations
      The following table shows the Company's current expectations for its full year 2015 financial performance.



      Expectations




      Gross sales increase


      16% - 20%




      Adjusted EBITDA


      $101 - $107 million




      Adjusted income from continuing

      operations per share


      $1.62 - $1.75




      Reduction of debt, net of cash


      $5 - 10 million




      Capital expenditures


      $80 - $85 million




      Depreciation


      $23 - $25 million




      Effective tax rate


      33% - 36%

      Consistent with prior years, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, restructuring activities and outcomes of tax disputes.  Sales expectations exclude the impact of foreign currency.  Adjusted EBITDA and Adjusted income from continuing operations per share are computed on a basis consistent with the reconciliation of the 2014 results in the tables at the end of this release.  The tax rate and amount of cash taxes paid will be sensitive to the geographic mix of income, and quarterly effective tax rates may be volatile. 

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's 2014 Form 10-K is filed with the SEC.

      Conference Call and Webcast
      A conference call to discuss the Company's fourth quarter and full year 2014 results will begin at 8:30 a.m. Eastern Time on Friday, February 6, 2015 and can be accessed by calling 1-888-713-3590 for domestic and +1-913-312-0696 for international.  Please use the passcode 2673922 and call approximately 10 minutes prior to the start time.  A webcast will be available in the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Friday, February 13, 2015 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the passcode 2673922 to access the replay. 

      About Cambrex
      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

      Forward Looking Statements
      This document contains "forward-looking statements," including statements or tables regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," and those attributed to our President and Chief Executive Officer in this document.  These and other forward looking statements may be identified by the fact that they use words such as "guidance," "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2013 and the Company's Annual Report on Form 10-K for the period ended December 31, 2014, once filed with the SEC,  captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of our customers' products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing of orders and the Company's ability to meet its production plan and its customer delivery schedules, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products and continued demand in the U.S. for late stage clinical products or the successful outcome of the Company's investment in new products.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, once filed with the SEC, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

      Use of Non-GAAP Financial Measures
      EBITDA and Adjusted Income from Continuing Operations are non-GAAP financial measures.  The Company defines EBITDA as operating profit plus depreciation and amortization expense and Adjusted Income from Continuing Operations is calculated in a manner consistent with that shown in the tables at the end of this release.   Other companies may have a different definition of EBITDA and Adjusted Income from Continuing Operations, therefore, these measures may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA and Adjusted Income from Continuing Operations should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA and Adjusted Income from Continuing Operations among several other metrics to assess and analyze its operational results and trends.  Cambrex also believes EBITDA and Adjusted Income from Continuing Operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended December 31, 2014 and 2013

      (in thousands, except per-share data)













      2014



      2013





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      128,841




      $

      103,011



           Commissions, Allowances and Rebates


      628





      576



      Net Sales


      128,213





      102,435













           Other Revenues


      1,102





      601













      Net Revenues


      129,315





      103,036













           Cost of Goods Sold


      83,916


      65.1%



      69,098


      67.1%











      Gross Profit


      45,399


      35.2%



      33,938


      32.9%











      Operating Expenses










           Selling, General and Administrative Expenses


      13,755


      10.7%



      14,714


      14.3%

           Research and Development Expenses


      3,130


      2.4%



      2,840


      2.8%

      Total Operating Expenses


      16,885


      13.1%



      17,554


      17.0%











           Loss on Voluntary Pension Settlement


      7,170


      5.6%



      -



           Gain on Sale of Asset


      (1,234)


      1.0%



      -













      Operating Profit


      22,578


      17.5%



      16,384


      15.9%











      Other Expenses/(Income):










           Interest Expense, Net


      539





      595



           Equity in Losses of Partially-Owned Affiliates


      5





      605



           Other (Income)/Expenses, Net


      (21)





      107













      Income Before Income Taxes


      22,055


      17.1%



      15,077


      14.6%











           (Benefit)/Provision for Income Taxes


      (6,203)





      5,637













      Income from Continuing Operations

      $

      28,258


      21.9%


      $

      9,440


      9.2%











      Loss from Discontinued Operations, Net of Tax


      (373)





      (541)













      Net Income

      $

      27,885


      21.6%


      $

      8,899


      8.6%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.91




      $

      0.31



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)




      $

      (0.02)



         Net Income

      $

      0.90




      $

      0.29













      Diluted Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.89




      $

      0.30



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)




      $

      (0.01)



         Net Income

      $

      0.88




      $

      0.29













      Weighted Average Shares Outstanding










           Basic


      31,053





      30,353



           Diluted


      31,803





      31,166













      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Twelve Months Ended December 31, 2014 and 2013

      (in thousands, except per-share data)













      2014



      2013





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      374,150




      $

      317,212



           Commissions, Allowances and Rebates


      2,306





      1,351



      Net Sales


      371,844





      315,861













           Other Revenues


      2,769





      2,315













      Net Revenues


      374,613





      318,176













           Cost of Goods Sold


      250,815


      67.0%



      215,272


      67.9%











      Gross Profit


      123,798


      33.1%



      102,904


      32.4%











      Operating Expenses










           Selling, General and Administrative Expenses


      52,489


      14.0%



      47,568


      15.0%

           Research and Development Expenses


      13,075


      3.5%



      10,387


      3.3%

      Total Operating Expenses


      65,564


      17.5%



      57,955


      18.3%











           Loss on Voluntary Pension Settlement


      7,170


      1.9%



      -



           Gain on Sale of Asset


      (1,234)


      0.3%



      (4,680)


      1.5%











      Operating Profit


      52,298


      14.0%



      49,629


      15.6%











      Other Expenses/(Income):










           Interest Expense, Net


      2,174





      2,242



           Equity in Losses of Partially-Owned Affiliates


      4,623





      2,262



           Other (Income)/Expenses, Net


      (5)





      118













      Income Before Income Taxes


      45,506


      12.2%



      45,007


      14.2%











           (Benefit)/Provision for Income Taxes


      (12,627)





      14,732













      Income from Continuing Operations

      $

      58,133


      15.5%


      $

      30,275


      9.5%











      Loss from Discontinued Operations, Net of Tax


      (830)





      (4,360)













      Net Income

      $

      57,303


      15.3%


      $

      25,915


      8.2%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      1.89




      $

      1.00



         Loss from Discontinued Operations, Net of Tax

      $

      (0.03)




      $

      (0.14)



         Net Income

      $

      1.86




      $

      0.86













      Diluted Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      1.84




      $

      0.98



         Loss from Discontinued Operations, Net of Tax

      $

      (0.03)




      $

      (0.14)



         Net Income

      $

      1.81




      $

      0.84













      Weighted Average Shares Outstanding










           Basic


      30,763





      30,150



           Diluted


      31,643





      30,901













      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of December 31, 2014 and 2013

      (in thousands)















      December 31,



      December 31,

      Assets


      2014



      2013







      Cash and Cash Equivalents

      $

      45,518


      $

      22,745

      Trade Receivables, Net


      77,124



      71,276

      Other Receivables


      10,610



      12,943

      Inventories, Net


      85,630



      89,965

      Prepaid Expenses and Other Current Assets


      8,688



      5,631

        Total Current Assets


      227,570



      202,560







      Property, Plant and Equipment, Net


      163,567



      171,966

      Goodwill


      43,912



      38,670

      Intangible Assets, Net


      8,902



      4,011

      Investments in and Advances to Partially-Owned Affiliates


      665



      13,364

      Deferred Income Taxes


      38,424



      19,799

      Other Non-Current Assets


      4,032



      7,667







        Total Assets

      $

      487,072


      $

      458,037







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      43,670


      $

      29,052

      Deferred Revenue


      14,095



      20,121

      Accrued Expenses and Other Current Liabilities


      41,014



      48,098

        Total Current Liabilities


      98,779



      97,271







      Long-Term Debt


      60,000



      79,250

      Deferred Income Taxes


      10,545



      12,835

      Accrued Pension Benefits


      50,949



      40,123

      Other Non-Current Liabilities


      15,573



      18,338







        Total Liabilities

      $

      235,846


      $

      247,817







        Stockholders' Equity

      $

      251,226


      $

      210,220







        Total Liabilities and Stockholders' Equity

      $

      487,072


      $

      458,037

      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Twelve Months Ended December 31, 2014 and 2013

      (in thousands)









      Fourth Quarter 2014



      Fourth Quarter 2013








      Operating Profit

      $

      22,578



      $

      16,384








      Loss on Voluntary Pension Settlement


      7,170




      -








      Gain on Sale of Asset


      (1,234)




      -








      Adjusted Operating Profit


      28,514




      16,384








      Depreciation and Amortization


      5,911




      5,842








      Adjusted EBITDA

      $

      34,425



      $

      22,226


























































      Twelve Months 2014



      Twelve Months 2013








      Operating Profit

      $

      52,298



      $

      49,629








      Loss on Voluntary Pension Settlement


      7,170




      -








      Gain on Sale of Asset


      (1,234)




      (4,680)








      Adjusted Operating Profit


      58,234




      44,949








      Depreciation and Amortization


      23,826




      22,473








      Adjusted EBITDA

      $

      82,060



      $

      67,422

      CAMBREX CORPORATION


      Reconciliation of GAAP to non-GAAP Results


      For the Quarters and Twelve Months Ended December 31, 2014 and 2013


      (in thousands)





















      Fourth Quarter 2014


      Fourth Quarter 2013










      Diluted EPS





      Diluted EPS



      Income from Continuing Operations

      $

      28,258

      $

      0.89


      $

      9,440

      $

      0.30


















      Loss on Pension Settlement



      7,170


      0.23



      -


      -



      Stock-Based Compensation, Net of Tax1


      1,268


      0.04



      1,600


      0.05



      Gain on Sale of Asset, Net of Tax



      (847)


      (0.03)



      -


      -



      Amortization of Purchased Intangibles


      176


      0.01



      264


      0.01



      Release of Valuation Allowance on Tax Assets

      (11,719)


      (0.37)



      -


      -



      Tax Audit Settlement




      (3,948)


      (0.12)



      -


      -


















      Adjusted Income from Continuing Operations

      $

      20,358

      $

      0.64


      $

      11,304

      $

      0.36




















































      Twelve Months 2014


      Twelve Months 2013










      Diluted EPS





      Diluted EPS



      Income from Continuing Operations

      $

      58,133

      $

      1.84


      $

      30,275

      $

      0.98


















      Loss on Pension Settlement



      7,170


      0.23



      -


      -



      Stock-Based Compensation, Net of Tax1


      3,541


      0.11



      3,540


      0.11



      Loss on Acquisition of Zenara Shares


      4,122


      0.13



      -


      -



      Gain on Sale of Asset, Net of Tax



      (847)


      (0.03)



      (3,210)


      (0.10)



      Amortization of Purchased Intangibles


      863


      0.03



      1,137


      0.04



      Release of Valuation Allowance on Tax Assets

      (26,902)


      (0.85)



      -


      -



      Tax Audit Settlement




      (3,948)


      (0.12)



      -


      -



      Changes in Tax Laws




      -


      -



      (1,155)


      (0.04)


















      Adjusted Income from Continuing Operations

      $

      42,132

      $

      1.33


      $

      30,587

      $

      0.99

































      1   Tax rate estimated at 35% for stock-based compensation.

      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.